Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1

Conditions

Salivary Gland Neoplasms 1Ovarian Neoplasms 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 19Paclitaxel 6Trastuzumab 5Nivolumab 5palbociclib 4Carboplatin 4Biopsy 4lenvatinib 3Taxes 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Ipilimumab 3Immunoglobulin G 3Fulvestrant 3Cyclophosphamide 3Cetuximab 3trastuzumab deruxtecan 2tisotumab vedotin 2spartalizumab 2sargramostim 2gedatolisib 2fludarabine 2epacadostat 2capivasertib 2X-Rays 2Sunitinib 2Docetaxel 2Disulfides 2Cisplatin 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × RC48 antibody × Head & Neck × Clear all
NCT06003231 2026-06-01

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Seagen Inc.

Phase 2 Active not recruiting
120 enrolled
GynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡